Xenon Pharmaceuticals Inc. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d003a910-8bd3-4e05-8307-05cf418435b3/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-373.1M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-076650 |
| FY 2024 | $-279.3M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029149 |
| FY 2023 | $-214.1M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-023177 |
| FY 2022 | $-129.1M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-005582 |
| FY 2021 | $-79.0M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-008060 |
| FY 2020 | $-31.3M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009905 |
| FY 2019 | $-42.8M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-009385 |
| FY 2018 | $-38.0M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-009385 |
| FY 2017 | $-32.6M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004750 |
| FY 2016 | $-24.8M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003716 |
| FY 2015 | $-9.4M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014222 |
| FY 2014 | $11.1M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001612 |
| FY 2013 | $9.7M | 2013-01-01 – 2013-12-31 | evidence 0001564590-15-001612 |
| FY 2012 | $-3.2M | 2012-01-01 – 2012-12-31 | evidence 0001564590-15-001612 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Xenon Pharmaceuticals Inc. — all facts · Revenue · Net Income